New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics
Authors
Keywords
-
Journal
Annual Review of Medicine
Volume 74, Issue 1, Pages 125-139
Publisher
Annual Reviews
Online
2023-01-28
DOI
10.1146/annurev-med-043021-014919
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes
- (2022) Domenica M. Rubino et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes
- (2022) Dominik Dahl et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Creating the amylin story
- (2022) Thomas A. Lutz APPETITE
- Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
- (2022) John P. H. Wilding et al. DIABETES OBESITY & METABOLISM
- Tirzepatide Once Weekly for the Treatment of Obesity
- (2022) Ania M. Jastreboff et al. NEW ENGLAND JOURNAL OF MEDICINE
- LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept
- (2022) Tamer Coskun et al. Cell Metabolism
- Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
- (2022) W. Timothy Garvey et al. NATURE MEDICINE
- Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity
- (2021) Thomas A. Wadden et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
- (2021) Melanie Davies et al. LANCET
- Once-Weekly Semaglutide in Adults with Overweight or Obesity
- (2021) John P.H. Wilding et al. NEW ENGLAND JOURNAL OF MEDICINE
- Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists
- (2021) Jamy Ard et al. ADVANCES IN THERAPY
- Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity
- (2021) Domenica Rubino et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial
- (2021) Lone B Enebo et al. LANCET
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
- (2021) Julio Rosenstock et al. LANCET
- Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial
- (2021) Bernhard Ludvik et al. LANCET
- Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial
- (2021) Aditi R. Saxena et al. NATURE MEDICINE
- Another milestone in the evolution of GLP-1-based diabetes therapies
- (2021) Michael A. Nauck et al. NATURE MEDICINE
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
- (2021) Juan P. Frías et al. NEW ENGLAND JOURNAL OF MEDICINE
- Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
- (2021) David C W Lau et al. LANCET
- Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
- (2021) Stefano Del Prato et al. LANCET
- Treating the Chronic Disease of Obesity
- (2021) Mona Gossmann et al. MEDICAL CLINICS OF NORTH AMERICA
- Role of a Dual Glucose-Dependent Insulinotropic Peptide (GIP)/Glucagon-like Peptide-1 Receptor Agonist (Twincretin) in Glycemic Control: From Pathophysiology to Treatment
- (2021) Maria Chiara Pelle et al. Life-Basel
- Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial
- (2020) Thomas A. Wadden et al. Obesity
- GIP as a therapeutic target in diabetes and obesity: insight from incretin co-agonists
- (2020) Jens Juul Holst et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity
- (2020) Aaron S. Kelly et al. NEW ENGLAND JOURNAL OF MEDICINE
- Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5
- (2020) Robert F. Kushner et al. Obesity
- SELECT (Semaglutide effects on cardiovascular outcomes in people with overweight or obesity) rationale and design
- (2020) Donna H. Ryan et al. AMERICAN HEART JOURNAL
- A Role for GLP-1 in Treating Hyperphagia and Obesity
- (2020) Harvey J Grill ENDOCRINOLOGY
- Amylin brain circuitry
- (2020) Lavinia Boccia et al. PEPTIDES
- GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art
- (2020) Michael A. Nauck et al. Molecular Metabolism
- The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity
- (2020) Martin Friedrichsen et al. DIABETES OBESITY & METABOLISM
- 2020: It Was Quite a Year!
- (2020) Donna H. Ryan et al. Obesity
- Semaglutide as a promising antiobesity drug
- (2019) Georgios A. Christou et al. Obesity Reviews
- Effects of liraglutide on appetite, food preoccupation, and food liking: results of a randomized controlled trial
- (2019) Jena Shaw Tronieri et al. INTERNATIONAL JOURNAL OF OBESITY
- Glucagon Receptor Signaling and Lipid Metabolism
- (2019) Katrine D. Galsgaard et al. Frontiers in Physiology
- The Discovery and Development of Liraglutide and Semaglutide
- (2019) Lotte Bjerre Knudsen et al. Frontiers in Endocrinology
- PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes
- (2019) Vanita R. Aroda et al. DIABETES CARE
- Long-acting CCK analogue NN9056 lowers food intake and body weight in obese Göttingen Minipigs
- (2019) Berit Ø. Christoffersen et al. INTERNATIONAL JOURNAL OF OBESITY
- The incretin system in healthy humans: The role of GIP and GLP-1
- (2019) Jens Juul Holst METABOLISM-CLINICAL AND EXPERIMENTAL
- Glucose-Dependent Insulinotropic Polypeptide Receptor-Expressing Cells in the Hypothalamus Regulate Food Intake
- (2019) Alice E. Adriaenssens et al. Cell Metabolism
- Oral Semaglutide: A Review of the First Oral Glucagon-Like Peptide-1 Receptor Agonist
- (2019) John D. Bucheit et al. Diabetes Technology & Therapeutics
- Glucagon-like peptide 1 (GLP-1)
- (2019) T.D. Müller et al. Molecular Metabolism
- Targeting the Incretin/Glucagon System with Triagonists to Treat Diabetes
- (2018) Megan E Capozzi et al. ENDOCRINE REVIEWS
- The Gut-Brain Axis, the Human Gut Microbiota and Their Integration in the Development of Obesity
- (2018) Edward S. Bliss et al. Frontiers in Physiology
- Amylin – Its role in the homeostatic and hedonic control of eating and recent developments of amylin analogs to treat obesity
- (2018) Christina Neuner Boyle et al. Molecular Metabolism
- Obesity as a Disease: The Obesity Society 2018 Position Statement
- (2018) Ania M. Jastreboff et al. Obesity
- LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
- (2018) Tamer Coskun et al. Molecular Metabolism
- Obesity Pathogenesis: An Endocrine Society Scientific Statement
- (2017) Michael W Schwartz et al. ENDOCRINE REVIEWS
- 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
- (2017) Carel W le Roux et al. LANCET
- The Cardiovascular Biology of Glucagon-like Peptide-1
- (2016) Daniel J. Drucker Cell Metabolism
- Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events
- (2016) Rohan Khera et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Obesity Impairs the Action of the Neuroendocrine Ghrelin System
- (2016) Jeffrey M. Zigman et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- GLP-1 receptor agonists and SGLT2 inhibitors: a couple at last?
- (2016) Michael A Nauck et al. Lancet Diabetes & Endocrinology
- Hypothalamic Amylin Acts in Concert with Leptin to Regulate Food Intake
- (2015) Zhiying Li et al. Cell Metabolism
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes
- (2015) Melanie J. Davies et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide
- (2015) Jesper Lau et al. JOURNAL OF MEDICINAL CHEMISTRY
- Islet α cells and glucagon—critical regulators of energy homeostasis
- (2015) Jonathan E. Campbell et al. Nature Reviews Endocrinology
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
- (2015) Xavier Pi-Sunyer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Leptin Is Associated With Exaggerated Brain Reward and Emotion Responses to Food Images in Adolescent Obesity
- (2014) Ania M. Jastreboff et al. DIABETES CARE
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
- (2014) Anna Secher et al. JOURNAL OF CLINICAL INVESTIGATION
- Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight
- (2014) Laurie L. Baggio et al. JOURNAL OF CLINICAL INVESTIGATION
- Amylin Modulates the Mesolimbic Dopamine System to Control Energy Balance
- (2014) Elizabeth G Mietlicki-Baase et al. NEUROPSYCHOPHARMACOLOGY
- Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study
- (2013) T A Wadden et al. INTERNATIONAL JOURNAL OF OBESITY
- Amylin Receptor Signaling in the Ventral Tegmental Area is Physiologically Relevant for the Control of Food Intake
- (2013) Elizabeth G Mietlicki-Baase et al. NEUROPSYCHOPHARMACOLOGY
- An overview of the pharmacokinetics, efficacy and safety of liraglutide
- (2012) Bruce Bode DIABETES RESEARCH AND CLINICAL PRACTICE
- Control of energy homeostasis by amylin
- (2011) Thomas A. Lutz CELLULAR AND MOLECULAR LIFE SCIENCES
- Do the Actions of Glucagon-Like Peptide-1 on Gastric Emptying, Appetite, and Food Intake Involve Release of Amylin in Humans?
- (2010) Meena Asmar et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now